Praxis Precision (PRAX) Medicines announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. TD Cowen, Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Buy Rating for Praxis Precision Medicines Driven by Ulixacaltamide’s Promising Phase III Results and Market Potential
- Praxis Precision price target raised to $441 from $83 at JonesResearch
- Promising Potential of Praxis Precision Medicines: Buy Rating on Ulixacaltamide’s Strong Phase 3 Results and Market Opportunity
- Praxis Precision price target raised to $232 from $115 at H.C. Wainwright
- Praxis Precision price target raised to $250 from $115 at Oppenheimer